Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
TORONTO, June 07, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held earlier today (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 19, 2024 (the "Circular") to its Shareholders were approved.
多倫多，2024年6月7日（環球新聞社）——Spectral Medical Inc.（“Spectral” or the “Company”）（TSX: EDT）是一家後期成長期的治療酸中毒和膿毒症的公司，致力於推進治療選擇方案，在今天宣佈了股東大會（“Shareholders”）的年度會議（“Meeting”）的結果。該公司確認，其向股東提出的所有決議都獲得通過，這些決議列在2024年4月19日的管理信息通告（“Circular”）中。
Results of the matters voted on at the Meeting are set out below.
股東大會上投票的議案結果如下所示。
Election of Directors
董事選舉
Spectral's seven director nominees were elected:
Spectral的七位董事候選人當選：
| Nominee | Votes For (percent) | Votes Withheld (percent) |
| Jan D'Alvise | 99.06% | 0.94% |
| Jun Hayakawa | 99.69% | 0.31% |
| Chris Seto | 86.08% | 13.92% |
| William Stevens | 99.06% | 0.94% |
| Paul Walker | 97.86% | 2.14% |
| David W. Feigal, Jr. | 99.59% | 0.41% |
| Cristiano Franzi | 99.73% | 0.27% |
| 提名人 | 贊成票數（百分比） | 反對票數（百分比） |
| Jan D'Alvise | 99.06% | 0.94% |
| Jun Hayakawa | 99.69% | 0.31% |
| Chris Seto | 86.08% | 13.92% |
| William Stevens | 99.06% | 0.94% |
| Paul Walker | 97.86% | 2.14% |
| David W. Feigal, Jr. | 99.59% | 0.41% |
| Cristiano Franzi | 99.73% | 0.27% |
Appointment of Auditors
核數師任命
PricewaterhouseCoopers LLP, Chartered Accountants, was re-appointed as auditor of Spectral.
PricewaterhouseCoopers LLP，特許會計師事務所，已被重新任命爲Spectral的核數師。
Votes For: 95.01%
贊成票數：95.01%
Votes Withheld: 4.99%
反對票數：4.99%
About Spectral
關於Spectral
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin ("PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA), the only FDA cleared diagnostic for the risk of developing sepsis.
Spectral是一家第三階段的公司，正在尋求美國FDA批准其用於治療膿毒症患者的獨特產品Toraymyxin（“PMX”）。PMX是一種治療性的血液灌流設備，可從血液中去除可能導致膿毒症的內毒素，並由公司的內毒素活性測定（EAA）指導，這是唯一獲得FDA批准用於膿毒症風險診斷的診斷方法。PMX已獲得日本和歐洲的治療使用批准，並已安全有效地治療了超過340,000名患者。
PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxemic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.
2022年7月，美國FDA授予PMX用於治療內毒素性膿毒症的突破性設備認證。每年大約有33萬名北美患者被診斷爲膿毒症休克。
The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis
Tigris試驗是對150名患者的治療性研究，旨在確定PMX與標準治療相結合與單獨使用的療效，採用貝葉斯統計學方法。內毒素性膿毒症是膿毒症惡性形式。
The trial methods are detailed in "Bayesian methods: a potential path forward for sepsis trials".
試驗方法詳見“貝葉斯方法：膿毒症試驗的潛在路徑”。
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit .
Forward-looking statement
Spectral在tsx交易所的標的是EDT。如需更多資訊，請訪問。
前瞻性聲明
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
本新聞發佈中未涉及當前或歷史事實數據的信息可能構成符合證券法定義的前瞻性信息。這些信息中有一些是隱含於Spectral的未來展望和預期事件或結果中的，這些展望或結果基於Spectral高級管理層的信仰和目前可得的信息所做的假設。雖然這些假設在Spectral 編制時被視爲合理的，但它們可能被證明是不正確的。讀者應該注意，實際結果受許多風險和不確定因素的影響，包括可用於開展生物醫藥業務和研發項目的資金和資源的可用性，臨床研究的成功並及時完成，Spectral利用生物醫藥行業中的商業機會的能力，監管機構批准的獲得以及總體經濟，市場和商業條件，並可能與目前的預期存在重大差異。
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
tsx未對此聲明進行審查，也不對其充分性或準確性負責。
For further information, please contact:
如需更多信息，請聯繫：
Ali Mahdavi
Capital Markets & Investor Relations
Spinnaker Capital Markets Inc.
416-962-3300
am@spinnakercmi.com
Ali Mahdavi
資本市場和投資者關係
Spinnaker資本市場業務公司
416-962-3300
am@spinnakercmi.com
譯文內容由第三人軟體翻譯。